Tempus AI, Inc. - SIC # 8071 - MEDICAL LABORATORIES

Ticker Exchange SIC # Website Latest Ticker
TEM Nasdaq 8071 www.tempus.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Tempus AI, Inc.

Tempus Al, Inc. (TEM) Opens Open-Source Digital Pathology Consortium - Jun 16th, 2026 6:52 am
Tempus AI (TEM) Stock After 23% Year-To-Date Decline Is Opportunity Emerging - Jun 12th, 2026 8:10 pm
Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm - Jun 11th, 2026 6:30 am
Tempus AI (TEM) Is One Of The Best Healthcare Mid-Cap AI Stock According To Analysts - Jun 10th, 2026 3:24 am
Genetics in Medicine Open Study Demonstrates How Ambry Genetics’ ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing - Jun 9th, 2026 4:00 am
Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - Jun 5th, 2026 2:01 pm
Assessing Tempus AI (TEM) Valuation After Recent Share Price Rebound And Underpriced Growth Narrative - Jun 5th, 2026 9:15 am
Tempus (TEM) Gets Double-Digit Boost from New Partnerships - Jun 4th, 2026 7:17 pm
Why Is Tempus (TEM) Down 11.2% Since Last Earnings Report? - Jun 4th, 2026 9:30 am
Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members - Jun 3rd, 2026 6:30 am
H.C. Wainwright Maintains Buy Rating on Tempus AI (TEM) Following Strong Revenue Growth - Jun 2nd, 2026 3:38 am
Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH - Jun 1st, 2026 6:30 am
Tempus AI (TEM) Is Up 9.3% After New FDA-Cleared CDx And AI Oncology Platform Upgrades - Jun 1st, 2026 12:12 am
Short Report: Tempus AI short interest at record high - May 31st, 2026 11:05 pm
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development - May 31st, 2026 6:30 am
Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community - May 30th, 2026 6:30 am
Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results - May 30th, 2026 6:00 am
How The Tempus AI (TEM) Investment Story Is Shifting As Analysts Rework Their Models - May 29th, 2026 11:02 pm
Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology - May 29th, 2026 7:15 am
Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio - May 29th, 2026 6:15 am